Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation

Cancer

Volumn 101, Issue 10, 2004, Pages 2261-2269

  Buesa, José M ^a,c   Losa, Raquel ^a   Fernández, Aida ^a   Sierra, Marta ^a   Esteban, Emilio ^a   Díaz, Ángela ^a   López Pousa, Antonio ^b   Fra, Joaquín ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Dacarbazine; Gemcitabine; Phase I trial; Soft tissue sarcoma

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; AMINOTRANSFERASE; DACARBAZINE; DEXAMETHASONE; DRUG METABOLITE; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HEMOGLOBINOPATHY; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOXURIDINE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SARCOMA; TREATMENT OUTCOME;

EID: 7644241820     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20612     Document Type: Article

References (35)

1. Brennan MF, Alektiar KM, Maki RG. Sarcomas of the soft tissue and bone. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology (6th edition). Philadelphia: Lippincott Williams & Wilkins, 2001:1841-1891.
2. Spath-Schwalbe E, Genvress I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs. 2000;11:325-329.
3. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a Phase II study. Cancer Chemother Pharmacol. 2000;45:177-181.
4. Plunkettt W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action and self-potentiation. Semin Oncol. 1995;22:3-10.
5. Grunewald R, Abbruzzese JL, Tarasoff P, Plunkett W. Saturation or 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27:258-262.
6. Abbruzzese JL, Grunewald R, Weeks EA, et al. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
7. Brand R, Capadano M, Tempero M. A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997;15:331-341.
8. Touroutoglou N, Gravel M, Raber N, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998;9:1003-1008.
9. Ulrich-Pur H, Kornek GV, Raderer M, et al. A Phase I trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer. 2000;88:2505-2511.
10. Friedman HS, Averbuch SD, Kurtzberg J. Nonclassic alkylating agents. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy (3rd edition). Philadelphia: Lippincott Williams & Wilkins, 2001:415-446.
11. Buesa JM, Urréchaga E. Clinical pharmacokinetics of high-dose DTIC. Cancer Chemother Pharmacol. 1992;28:475-479.
12. Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ. Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep. 1984;68:499-504.
13. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976;60:199-203.
14. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991;2:307-309.
15. National Cancer Institute Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. Bethesda: National Cancer Institute, 1998.
16. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
17. Kroep JR, Giaconne G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J Clin Oncol. 1999;17:2190-2197.
18. Losa R, Sierra MI, Blay P, Blanco D, Buesa JM. Determination of gemcitabine triphosphate in peripheral blood mononuclear cells by reverse-phase HPLC. Chromatographia. 2004;59:7-8.
19. Martin C, Pollera CF. Gemcitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res. 1996;16:9-18.
20. Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a Phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15:310-316.
21. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
22. Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001;12:183-186.
23. Ceci G, Bella M, Melissari M, Gabrielli M, Bocchi P, Cocconi G. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer. 1988;61:1988-1991.
24. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a Phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992;10:406-413.
25. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 1990;50:6823-6826.
26. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483-3489.
27. Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a Phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002;20:665-673.
28. Svancarova L, Blay JL, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38:556-559.
29. Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). A trial of the Eastern Cooperative Oncology Group. Cancer. 2003;97:1969-1973.
30. Burton GV, Rankin C, Flaherty LE, et al. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol. 2003;22:820.
31. Amodio A, Carpano S, Manfredi C, et al. Gemcitabine in advanced stage soft tissue sarcoma: a Phase II study. Clin Ther. 1999;150:17-20.
32. Samuels BL, Barbour L, Schiller D. Phase I study of low dose continuous infusion gemcitabine in sarcoma patients [abstract]. Proc Am Soc Clin Oncol. 2001;20:296b.
33. Gautam U, Hurley J, Silva OE, et al. Gemcitabine: an active chemotherapeutic agent for angiosarcoma [abstract]. Proc Am Soc Clin Oncol. 2002;21:278b.
34. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J Clin Oncol. 2002;20:2824-2831.
35. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of osteosarcoma. J Clin Oncol. 2004;22:1706-1712.